US EditionGene-editing therapy OTQ923 cuts stroke risk in 3 SCD patients
Summary by Sickle Cell Disease News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Gene-editing therapy OTQ923 cuts stroke risk in 3 SCD patients
The investigational gene-editing therapy OTQ923 resulted in normalization of the speed of blood flow in the brain of three adults with sickle cell disease (SCD), according to data from a Phase 1 clinical trial. Findings suggest the treatment could help lower the risk of stroke in patients. The study (NCT04443907), sponsored by Novartis Pharmaceuticals, was stopped early due to commercial reasons, as the company discontinued its SCD gene-editing …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
